Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 527,914
  • Shares Outstanding, K 327,897
  • Annual Sales, $ 4,060 K
  • Annual Income, $ -54,050 K
  • EBIT $ -60 M
  • EBITDA $ -58 M
  • 60-Month Beta 2.75
  • Price/Sales 129.29
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 118.21% (-14.32%)
  • Historical Volatility 73.33%
  • IV Percentile 24%
  • IV Rank 7.03%
  • IV High 544.02% on 11/14/25
  • IV Low 86.00% on 01/08/26
  • Expected Move (DTE 11) 0.3570 (21.57%)
  • Put/Call Vol Ratio 0.30
  • Today's Volume 610
  • Volume Avg (30-Day) 1,407
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 63,565
  • Open Int (30-Day) 59,405
  • Expected Range 1.2980 to 2.0120

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.07
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3600 +19.49%
on 02/11/26
2.0000 -18.75%
on 03/04/26
+0.2450 (+17.75%)
since 02/09/26
3-Month
1.1900 +36.55%
on 12/10/25
2.0000 -18.75%
on 03/04/26
+0.4150 (+34.30%)
since 12/09/25
52-Week
0.5150 +215.53%
on 03/19/25
2.0000 -18.75%
on 03/04/26
+1.0148 (+166.31%)
since 03/07/25

Most Recent Stories

More News
Ocugen: Q4 Earnings Snapshot

Ocugen: Q4 Earnings Snapshot

OCGN : 1.6150 (+0.31%)
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected...

OCGN : 1.6150 (+0.31%)
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END

AVAI : 0.3690 (+1.82%)
NAGE : 5.18 (+2.37%)
GERN : 1.5550 (+1.63%)
NTLA : 13.60 (+1.19%)
OCGN : 1.6150 (+0.31%)
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patients...

OCGN : 1.6150 (+0.31%)
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results

MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it...

OCGN : 1.6150 (+0.31%)
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment...

OCGN : 1.6150 (+0.31%)
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously...

OCGN : 1.6150 (+0.31%)
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten...

OCGN : 1.6150 (+0.31%)
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. control There are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 clinical...

OCGN : 1.6150 (+0.31%)
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

OCGN : 1.6150 (+0.31%)

Business Summary

Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 1.8900
2nd Resistance Point 1.8300
1st Resistance Point 1.7200
Last Price 1.6150
1st Support Level 1.5500
2nd Support Level 1.4900
3rd Support Level 1.3800

See More

52-Week High 2.0000
Last Price 1.6150
Fibonacci 61.8% 1.4327
Fibonacci 50% 1.2575
Fibonacci 38.2% 1.0823
52-Week Low 0.5150

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar